婴儿口服肠道疫苗开发中的技术产品属性
本文基于第二届志贺菌与产肠毒素大肠杆菌疫苗国际会议(VASE会议)的工作坊,讨论婴儿口服肠道疫苗开发的首选产品属性。工作坊旨在识别差距并汇集临床前、工艺开发、生产、监管和临床领域专家的意见,以细化婴儿口服疫苗开发的关键目标产品属性,并参考已上市婴儿口服疫苗探讨防腐剂、多剂量瓶和抗酸缓冲液呈现形式等潜在改进。
要点
- 婴儿口服肠道疫苗开发对志贺菌和产肠毒素大肠杆菌(ETEC)疫苗研发具有重要意义。
- 工作坊汇集多领域专家意见,旨在细化婴儿口服疫苗的关键目标产品属性。
- 已上市婴儿口服疫苗的防腐剂、多剂量瓶和抗酸缓冲液形式可供新型疫苗开发参考。
核心结论
- 工作坊通过专家意见识别差距并细化婴儿口服肠道疫苗开发的关键目标产品属性。
研究设计与样本
- 基于第二届VASE会议工作坊的专家讨论,汇集临床前、工艺开发、生产、监管和临床领域专家意见。
主要发现
- 工作坊利用已上市婴儿口服疫苗示例,探讨了防腐剂、多剂量瓶和抗酸缓冲液呈现形式(液体或冻干)等潜在改进方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Development of an oral enteric vaccine for infants is important for Shigella and enterotoxigenic Escherichia coli (ETEC) vaccine development. At a recent workshop titled "Technical Product Attributes in Development of an Oral Enteric Vaccine for Infants," at the 2nd International Vaccines Against Shigella and ETEC Conference (VASE Conference), the preferred product attributes for development were discussed for these vaccines. The aims of this workshop were to identify gaps and gather opinions from key experts from preclinical, process development, manufacturing, regulatory, and clinical areas to fine-tune and refine key target product attributes for infant oral vaccine development. The workshop used some examples of marketed oral infant vaccines to discuss potential improvements that can be made, such as inclusion of preservatives, multidose vials, and antacid buffer presentation (liquid or lyophilized) in novel oral enteric vaccine development.
引用
- White JA, Lal M. Technical product attributes in development of an oral enteric vaccine for infants. Vaccine. 2019. PMID: 31358239. doi:10.1016/j.vaccine.2019.02.060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。